Neuroscience-focused Neurocrine Biosciences has won US Food and Drug Administration (FDA) approval for Ingrezza (valbenazine) capsules to treat adults with chorea associated with Huntington's disease (HD). 21 August 2023
US rare and orphan dermatologic diseases firm Timber Pharmaceuticals saw it shares almost double to $2.79 this morning, on the news of a takeover bid. 21 August 2023
UK addiction treatment specialist Indivior (LSE/Nasdaq: INDV) saw its shares edge up 3% to 1,812 pence by early afternoon, as it revealed a resolution to the claims brought by the end payor class of litigants in the In re Suboxone Antitrust Litigation multi-district litigation (MDL). 21 August 2023
Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
US biotech Selecta Biosciences is to freeze investment on all pipeline assets except SEL-212, which is being developed for the treatment of chronic refractory gout. 18 August 2023
Massachusetts, USA-based cell therapy specialist Abcuro has raised $155 million in a series B financing round co-led by Redmile Group and Bain Capital Life Sciences. 17 August 2023
The US Food and Drug Administration (FDA) has told bluebird bio that an advisory committee (AdCom) meeting will not be scheduled for lovotibeglogene autotemcel (lovo-cel). 17 August 2023
US clinical stage biotech Day One Biopharmaceuticals has entered into an exclusive, global license agreement and research collaboration with Sweden’s Sprint Bioscience for rights to the latter’s VRK1 program. 17 August 2023
Privately-held drugmaker Chiesi has secured approval from the British medicines regulator for Elfabrio (pegunigalsidase alfa) in Fabry disease (FD). 16 August 2023
Chiesi Global Rare Diseases, a business unit of privately-held Italian drugmaker Chiesi Farmaceutici established to deliver innovative therapies and solutions for people living with rare diseases, has announced a co-development agreement with Aliada Therapeutics. 16 August 2023
US-incorporated clinical-stage biotech Galecto saw its shares close down more than 71% at $0.67 yesterday, after it revealed disappointing clinical trial results for a lead investigational drug. 16 August 2023
US biotech major Gilead Sciences has entered into three, multi-year, collaborations with San Diego-based start-up Tentarix Biotherapeutics. 15 August 2023
Swedish biopharma Calliditas Therapeutics continues to press for full approval of Nefecon/Tarpeyo (budesonide) delayed release capsules/Kinpeygo. 15 August 2023
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
US developer of rare neurological drugs Harmony Biosciences on Monday revealed it has reached a definitive agreement to acquire Zynerba Pharmaceuticals
. 15 August 2023
The US Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma (rrMM), under development by US biotech Arcellx. 15 August 2023
US clinical-stage drug developer Taysha Gene Therapies saw its share price leap 133% to $1.72 yesterday, after it announced a securities purchase agreement for a private placement financing (the PIPE) that is expected to result in gross proceeds of about $150 million, before deducting placement agent commissions and offering expenses. 15 August 2023
In a Securities and Exchange Commission (SEC) filing last Friday, US oncology focused biotech Syros Pharmaceuticals disclosed it has received notice from Incyte Corp that it was opting out of a blood cancer treatment collaboration. 14 August 2023
Privately-held Resolution Therapeutics, a UK biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, has named Amir Hefni as chief executive. 14 August 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024